A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial

INTRODUCTION: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. METHODS: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatment-naive, advanced NSCLC to assess the safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Jeffrey M., Gu, Lin, Wang, Xiaofei F., Stinchcombe, Thomas E., Stevenson, Marvaretta M., Ramalingam, Sundhar, Shariff, Afreen, Garst, Jennifer, Nixon, Andrew B., Antonia, Scott J., Crawford, Jeffrey, Ready, Neal E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204732/
https://www.ncbi.nlm.nih.gov/pubmed/35719867
http://dx.doi.org/10.1016/j.jtocrr.2022.100337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204732/
https://www.ncbi.nlm.nih.gov/pubmed/35719867
http://dx.doi.org/10.1016/j.jtocrr.2022.100337

Ejemplares similares